Navigation Links
Dendreon Announces Closing of Common Stock Offering
Date:5/13/2009

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the closing of its previously reported underwritten public offering of 10,700,000 shares of its common stock, which shares were offered for sale to the public at $19.20 per share. On May 8, 2009, Deutsche Bank Securities Inc., acting as sole manager of the offering, exercised in full its over-allotment option to purchase an additional 1,279,166 shares of common stock at the public offering price of $19.20 per share. The exercise of the option increased the size of the offering to an aggregate of 11,979,166 shares of common stock.

Dendreon received net proceeds from the offering of approximately $221 million, after deducting underwriting commissions and estimated offering expenses. Dendreon plans to use the net proceeds of the offering to develop manufacturing facilities, a distribution network, an information technology platform and other infrastructure, to hire sales and marketing, manufacturing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE(R) (sipuleucel-T), and for general corporate purposes, including working capital.

Copies of the prospectus supplement relating to the offering may be obtained by contacting: Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, telephone: 1-800-503-4611.

Shelf registration statements relating to the sale of the securities were filed with the Securities and Exchange Commission and were effective on August 29, 2008 and May 7, 2009. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale woul
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix" or the ... recent significant market drop of Resverlogix shares management ... fundamentals remain the same if,not stronger in regards ... no reason for the price drop other than ...
... AMERIGROUP,Corporation (NYSE: AGP ) today announced that ... ended September 30, 2008, after the market closes ... Time on Thursday, October,23, 2008, AMERIGROUP,s management will ... and other information., To listen to the ...
... Mass., Oct. 7 BioEnergy International, LLC,(BioEnergy), ... renewable biochemicals and biofuels, announces the,addition of ... Advisors effective December,2008. Mr. Augustine has a ... highest level of industry and government culminating ...
Cached Biology Technology:AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... commerce market releases photos and video of the recent opening bell ... th . Gino Pereira , CEO of ... Mr. Chad A. Verdi rang the bell.  ... and employees "for their work and dedication in bringing the world,s ...
(Date:10/14/2014)... published in Cancer Research shows SIRT6—a protein ... cancers—can promote the development of skin cancers by turning ... of sun-damaged skin cells. , Previously considered protective, SIRT6 ... sirtuins that help regulate genomic stability and prevent some ... repair DNA damage, which can lead to cancer. This ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... vessels in the body, called "angiogenesis," is usually discussed in ... ongoing process in the female reproductive tract, where the growth ... the menstrual cycle. But abnormal growth of blood vessels can ... Ruth Shalgi and research associate Dr. Dana Chuderland of Tel ...
... , April 3, 2013  NAPCO Security Technologies, Inc., (NASDAQ: ... suppliers of high performance electronic security equipment for over ... - West Conference and Exhibition , at the Sands Convention ... 2013. ISC West is one of the largest events in ...
... energy or one that,s environmentally destructive? That,s the question ... Society Forum session on fracking April 10, 2013 from 3 ... NJIT Technology and Society Forum is free and open to ... underground at high pressure to fracture rock formations in order ...
Cached Biology News:New relief for gynecological disorders 2New relief for gynecological disorders 3NAPCO Security Technologies, Inc. to Demonstrate New Product Capabilities at 2013 ISC West Conference and Exhibition 2NAPCO Security Technologies, Inc. to Demonstrate New Product Capabilities at 2013 ISC West Conference and Exhibition 3Fracking: Challenges and opportunities 2
... the computing power of your ValveBank system! ... sequences with a Macintosh computer using graphic ... to disk, print out program listings, then ... in one simple step., EasyCode is used ...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
... is a dedicated fluorometer with ... kinds of assays in industrial ... clinical applications. Cell biology, immunology ... important application areas. Robot-friendly hardware ...
... class-leading features, the 1400 Series will maximize your comfort ... consistent every time you use it. , ... consumption by as much as 50% from competitive models, ... the cabinet. Multiply this savings by the number ...
Biology Products: